Obermatt
See Similar Stocks →

Denali Therapeutics

NSQ:DNLI · US24823R1059
BiotechnologySmall

360

37
Medium confidence — indicative
Profit price34
Owner Earnings Yield1
Dividend Yield1
Price/Sales15
Price/Book9
Return on Capital21
Cash Return on Capital26
Return on Equity29
Profit margins9

Cash truth not applicable for financial companies.

Sales growth—
Profit Growth8
Long-Term EPS Growth26
Reinvestment39
Price momentum58
Debt load68
Refinancing51
Debt Payback1
Liquidity34
Analyst ratings68
Opinion Changes50
Price Target Upside54
Market mood48
Value Creation2/20not creating value
  • Creates more value than its capital costs
  • Owner earnings growing
  • Owner earnings per share growing
  • Reinvests at strong returns
  • Solid earnings base

What this means

Denali Therapeutics doesn't consistently earn more than its cost of capital, so it isn't yet creating shareholder value.

Based on 4/5 components.

Profile

CountryUSA
IndustryBiotechnology
SizeSmall
TypePublic Company
ExchangeNASDAQGS
Founded2013
Employees538
Websitedenalitherapeutics.com
ISINUS24823R1059
Last UpdateApr 2, 2026
Indices
NASDAQ (USA)
Themes
NeurologyChronic DiseasesInflammationImmunologyOncologyGeneticsNeuroscienceCentral Nervous SystemBiotechnologyHealth DiagnosticsTherapeutics

Description

Denali Therapeutics Inc. (‘Denali’), a biopharmaceutical company, discovers and develops therapeutics to defeat neurodegenerative diseases and lysosomal storage diseases. The company has invented, developed, and validated a proprietary technology, c…

Analysis

Middle-of-the-road

Denali Therapeutics Inc. sits in the middle of our grid: average quality, average price, no obvious signal in either direction.

Valuation data is not available for this company.

Growth is moderate; the safety picture is adequate. The company scores 2/20 on our value-creation score: not creating value.

No flags apply to this company at this time: accounts, balance sheet, and cash quality all pass. A clean bill of health is meaningful, not just the absence of a warning. This analysis describes numbers; it is not investment advice.

360° rank · history

1007550250
20
2026

All-time high

31

Mar 2026

All-time low

20

Jun 2026

Average rank

26

across all years

Detailed & Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history.

Current202520242023
Price/Sales
15
—
—
—
Price/Earnings
65
—
—
—
Price/Book
9
—
—
—
Dividend Yield
1
—
—
—
Value (overall)
1
—
—
—

Cells are coloured by rank band (red weak → green strong). Sentiment & 360° history begins 2023.

Similar Stocks

The companies this stock is ranked against.

Compare Denali Therapeutics with its peers
Alector
NSQ:ALEC
15
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
Kodiak Sciences
NMQ:KOD
82
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
Abeona Therapeutics
NAQ:ABEO
89
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
MeiraGTx
NSQ:MGTX
18
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
Recursion Pharmaceuticals
NSQ:RXRX
20
CountryUSA
IndustryBiotechnology
SizeMedium
Full Stock Analysis →
Regenxbio
NSQ:RGNX
17
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →

Make Sense of the Ranks

Every rank runs 1–100 against true peers. Higher is always better.

360° View
1 · Watch OutGood· 100
Value
1 · ExpensiveGood Value· 100
Quality
1 · Weak FundamentalsHigh Quality· 100
Growth
1 · Tough TimesHigh Growth· 100
Safety
1 · High LeverageWell-Financed· 100
Sentiment
1 · SkepticismPositive· 100
Learn More →